The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1413
April 1, 2013
View Complete Issue         Table of Contents 2019 
Raxibacumab for Anthrax
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Raxibacumab for Anthrax
April 1, 2013 (Issue: 1413)
The FDA has approved raxibacumab (rax” ee bak’ ue mab; GSK), a fully human monoclonal antibody given by intravenous infusion, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs, and for prophylaxis of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Raxibacumab for Anthrax
Article code: 1413b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.